Immune function and phenotype before and after highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 5, 1999, Pages 376-383

  Søndergaard, Sisse R ^b   Aladdin, Hassan ^b   Ullum, Henrik ^b   Gerstoft, Jan ^b   Skinhøj, Peter ^b   Pedersen, Bente K ^a  

^a University of Copenhagen   (Denmark)

^b NONE

Author keywords

AIDS; CD4; CD8; Chemokines; CTL; Cytokines; HAART; HIV; LAK cells; NK cells; Proliferation

Indexed keywords

ANTIVIRUS AGENT; CD16 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; SYNAPSIN I;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMORY CELL; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; PHENOTYPE; PRIORITY JOURNAL; TELOMERE;

EID: 0032856046     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199908150-00004     Document Type: Article

References (32)

1. Li TS, Tubiana R, Katlama C, Calvez V, Ait MH, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
2. Pakker NG, Roos MT, van LR, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16: 318-26.
3. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177: 898-904.
4. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-16.
5. + lymphocytes during antiretroviral therapy. J Infect Dis 1997;176:1378-82.
6. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998;95:1154-1159.
7. Pakker NG, Notermans DW, de BR, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation [see comments]. Nat Med 1998;4:208-14.
8. + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996;10:F17-22
9. - T cells. AIDS 1994;8:431-441.
10. + T cells in HIV-1-infected patients. AIDS 1996;10:827-34.
11. Ullum H, Lepri AC, Bendtsen K, et al. Low production of IFNγ is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses 1997;13:1039-46.
12. Ullum H, Lepri AC, Victor J, et al. Production of β-chemokines in HIV infection: evidence that high levels of MIP-1β are associated with a decreased risk of HIV disease progression. J Infect Dis 1998;177:331-6.
13. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry [see comments]. Curr Opin Immunol 1997;9:551-62.
14. + cell suppression of HIV replication. J Immunol 1997;159:5123-31.
15. Guntermann C, Zheng R, Nye KE. The effects of CD3, CD4 and CD28 signaling on lymphocytes during human immunodeficiency virus-1 infection. Eur J Immunol 1997;27:1966-72.
16. Roederer M, Raju PA, Mitra DK, Herzenberg LA. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest 1997;99:1555-64.
17. Ullum H, Gotzsche PC, Victor J, Dickmeiss E, Skinhoj P, Pedersen BK. Defective natural immunity:an early manifestation of Human Immune deficiency Virus Infection. J Exp Med 1995;182:789-99.
18. Bruunsgaard H, Pedersen C, Skinhoj P, Pedersen BK. Clinical progression of HIV infection: role of NK cells. Scand J Immunol 1997;46:91-5.
19. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis 1997; 176:118-25.
20. Pontesilli O, Klein MR, Kerkhof GS, et al. Kinetics of immune functions and virus replication during HIV-1 infection. Immunol Lett 1997;57:125-30.
21. Roos M, Miedema F, Meinesz A, et al. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin Exp Immunol 1996;105:409-15.
22. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997;11:1111-18.
23. Walker BD. HIV-1-Specific cytotoxic T lymphocytes. In Aldovini A, Walker BD, eds. Techniques in HIV resarch. 1990;201-9.
24. Silvestri G, Munoz C, Butini L, Bagnarelli P, Montroni M. Changes in CD8 cell subpopulations induced by antiretroviral therapy in human immunodeficiency virus infected patients. Viral Immunol 1997;10:207-12.
25. Emery S, Lane HC. Immune reconstitution in HIV infection [see comments]. Curr Opin Immunol 1997;9:568-72.
26. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today 1997;18:245-51.
27. + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89:3700-7.
28. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90: 3789-98.
29. - cells with low lytic activity. J Acquire Immune Defic Syndr Hum Retrovirol 1995;10:331-40.
30. - cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 1997;180:132-42.
31. Bradstock KF, Luxford C, Grimsley PG. Functional and phenotypic assessment of neonatal human leukocytes expressing natural killer cell-associated antigens. Immunol Cell Biol 1993;71:535-42.
32. Jewett A, Bonavida B. Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol 1995;160:91-7.